RxDoctor Payments Data

George McLeod, MD

Cardiovascular Disease · Wilmington, NCNPI 1740523976

Payments from drug & device makers

$2,333in general payments, 2019–2025

Across 79 payments — averaging $29.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$750
  • AstraZeneca$274
  • Boston Scientific$253
  • Abbott$242
  • Medtronic$221
  • Novartis$125
  • plus $467 from 9 others

What the payments were for

  • Food & beverage$2,25897%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,333 in reported general payments places this provider in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$356,675
Medicare patients
2,559
Services billed
5,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$394,450
XareltoRivaroxaban112$138,025
Repatha SureclickEvolocumab80$122,089
FarxigaDapagliflozin Propanediol66$70,104
EntrestoSacubitril/Valsartan43$60,086
JardianceEmpagliflozin29$38,628
MultaqDronedarone Hcl11$17,594
Praluent PenAlirocumab13$16,340
BrilintaTicagrelor20$11,948
Metoprolol Succinate778$10,012
Atorvastatin Calcium632$6,925
Rosuvastatin Calcium425$4,793
Dofetilide16$4,223
Ezetimibe109$2,851
Losartan Potassium248$2,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$274$82,05286 claims
NovartisEntresto$125$60,08643 claims
Sanofi-aventis U.S. LLCMultaq$64$17,59411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →